Reshoring fine chemical and pharmaceutical productions

Prolonged shortage of active pharmaceutical ingredients (APIs) in many countries that do not produce critically important APIs requires urgent reshoring of the said fine chemical productions. The situation is even worsened by frequent disruption of the global supply chains, first during the COVID-19 crisis and subsequently with the ongoing Red Sea crisis. In this study, we first outline the main economic and policy aspects emerging from selected cases of reshoring of API production to Europe. Hence, broadening the analysis to include selected cases in China and India, we investigate the industrial uptake of continuous manufacturing in fine chemicals production. Following said concrete analysis of the concrete situation, the study concludes with three main findings.